Redeye comments on Fluoguide’s Q2 2023 report as top-line data from the company’s phase IIb trial in high-grade glioma are just around the corner in Q4 2023e. We judge that positive phase IIb HGG and phase IIa HNSCC data are critical to FG001’s clinical development, associated funding, and attracting potential partners.